

Table S1 Clinical characteristics of the patients with FELs included for imaging analysis

Item	Number of patients with FELs/mean \pm SD
Total number	33
Age (years)	
Mean \pm SD	55.73 \pm 10.10
Range	30–81
Male (mean \pm SD, range)	55.48 \pm 11.28, 30–81
Female (mean \pm SD, range)	56.50 \pm 5.43, 51–68
Sex (male/female)	25/8
Cancer	
Gastric cancer	28
pTNM	
I	1 (T1N0M0)
II	11 (T3N0M0, T3N1M0, T4aN0M0)
III	16 (T2N3aM0, T3N2M0, T3N3aM0, T4aN3aM0, T4bN2M0)
Colorectal cancer	5
pTNM	
II	4 (T3N0M0, T4N0M0)
III	1 (T2N1M0)

pTNM staging of gastric cancer and colorectal cancer refers to the UICC and AJCC staging system. FEL, fluorouracil encapsulated lesion; SD, standard deviation; pTNM, pathological tumor-node-metastasis; UICC, Union for International Cancer Control; AJCC, American Joint Committee on Cancer.

Table S2 Tumor types and TNM staging of patients with liver metastases

Type	Number of patients (TNM staging)
Gastric cancer	3
III	1 (pT3N3M0)
IV	2 (pT4N1M1)
Colorectal cancer	24
II	4 (pT3N0M0, ypT3N0M0)
III	8 (pT3N1M0, pT3N2M0, pT4N1M0, pT4N2M0, ypT4N2M0)
IV	12 (cT3N0M1, cT4N2M1, pT3N0M1, pT3N1M1, pT4N0M1, pT4N1M1)
Lung cancer	7
IV	cT2N0M1, cT3N2M1, cT4N0M1, cT4N3M1
Breast cancer	2
II	pT2N0M0, pT2N1M0
Thyroid cancer	1
IV	pTxNxM1
Ampullary cancer	1
IV	pT3N0M1
Gastric stromal tumor	1
IV	pT4N0M1
Cervical cancer	1
II	ypT2N0M0

TNM staging of the cancers mentioned above refers to the UICC and AJCC staging system. Patients with surgical resection are presented with pTNM/ypTNM staging. Patients treated conservatively are presented with cTNM staging at the time of liver metastasis. Due to the incomplete clinical data of the patient with thyroid cancer, we only recorded M staging. TNM, tumor-node-metastasis; pTNM, pathological tumor-node-metastasis; ypTNM, post-neoadjuvant tumor-node-metastasis; cTNM, clinical tumor-node-metastasis; UICC, Union for International Cancer Control; AJCC, American Joint Committee on Cancer.